HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dietary Supplement GMPs Back To FDA; Publication Expected In June

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement good manufacturing practices have received final clearance by the Office of Management and Budget, OMB and FDA confirmed May 9

You may also be interested in...



CRN Pushes Budget Office To Seek FDA Review Of NDI Notification Costs

The Council for Responsible Nutrition has gone to the White House budget office with its challenge of FDA’s estimate of the cost to comply with its new dietary ingredient notification guidance.

NSF GMP program

NSF International announces May 30 its good manufacturing practices readiness program, "One Step Ahead," which includes an online service center to help manufacturers prepare for the GMPs. NSF will audit facilities and note any non-conformances, giving firms opportunities to take corrective action before FDA audits. NSF's program offers a source book containing standard operating procedure templates and a trial self-audit tool. FDA and the Office of Management and Budget announced GMPs received final clearance from OMB on May 9 (1"The Tan Sheet" May 14, 2007, p. 5)...

Dietary Supplement GMP Spin-Off Reg May Address Small Business Impact

The Office of Management and Budget on May 23 completed reviewing an interim final rule related to dietary supplement good manufacturing practices FDA is expected to publish within six weeks, according to OMB.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel